A new trading day began on Monday, with BioXcel Therapeutics Inc (NASDAQ: BTAI) stock price up 38.45% from the previous day of trading, before settling in for the closing price of $0.41. BTAI’s price has ranged from $0.30 to $4.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 67.00%. Meanwhile, its annual earnings per share averaged 72.28%. With a float of $41.10 million, this company’s outstanding shares have now reached $42.46 million.
Let’s determine the extent of company efficiency that accounts for 74 employees. In terms of profitability, gross margin is 4.13%, operating margin of -3295.61%, and the pretax margin is -3119.33%.
BioXcel Therapeutics Inc (BTAI) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BioXcel Therapeutics Inc is 17.18%, while institutional ownership is 17.38%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 72.28% per share during the next fiscal year.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Here are BioXcel Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.15, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -1.34 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Looking closely at BioXcel Therapeutics Inc (NASDAQ: BTAI), its last 5-days average volume was 1.96 million, which is a drop from its year-to-date volume of 2.56 million. As of the previous 9 days, the stock’s Stochastic %D was 81.70%. Additionally, its Average True Range was 0.06.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 51.05%, which indicates a significant decrease from 98.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 161.73% in the past 14 days, which was higher than the 109.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5068, while its 200-day Moving Average is $1.1870. However, in the short run, BioXcel Therapeutics Inc’s stock first resistance to watch stands at $0.6281. Second resistance stands at $0.6831. The third major resistance level sits at $0.7876. If the price goes on to break the first support level at $0.4686, it is likely to go to the next support level at $0.3641. Should the price break the second support level, the third support level stands at $0.3091.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
With a market capitalization of 30.05 million, the company has a total of 49,629K Shares Outstanding. Currently, annual sales are 1,380 K while annual income is -179,050 K. The company’s previous quarter sales were 210 K while its latest quarter income was -13,650 K.
